Communiqués ProMIS Neurosciences, Inc.

Actions

PMN

CA74346M4065

Marché Fermé - Nasdaq Autres places de cotation 22:30:00 01/07/2024			Varia. 5j.	Varia. 1 janv.
1,6 ^USD	+6,67%		+0,63%	+39,13%

15/05	ProMIS Neurosciences, Inc. annonce ses résultats pour le premier trimestre clos le 31 mars 2024	CI
30/04	ProMIS Neurosciences, Inc. publie une étude soulignant la sélectivité des oligomères et les avantages des anticorps dirigés contre la bêta-amyloïde	CI

Communiqués

Débloquez toutes les actualités : Soyez le premier informé et réagissez avant les marchés !

Inscription 100% Gratuite

ProMIS Neurosciences Announces First Quarter 2024 Financial Results and Recent Highlights	14/05	AQ
ProMIS Neurosciences Publishes Study Highlighting Oligomer Selectivity and Benefit of Amyloid-Beta-Directed Antibodies	30/04	AQ
ProMIS Neurosciences Publishes in the Journal of Biological Chemistry on the Interaction Between Pathogenic Proteins as a Treatment Target for ALS	09/04	AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	05/04	AQ
ProMIS Neurosciences to Present in Upcoming Investor Conferences in April	04/04	AQ
ProMIS Neurosciences Announces Full Year 2023 Financial Results and Recent Highlights	01/04	AQ
ProMIS Neurosciences : Corporate Overview	29/03	PU
ProMIS Neurosciences Strengthens Global Intellectual Property Portfolio	11/03	AQ
ProMIS Neurosciences to Present at the 2024 BIO CEO & Investor Conference	22/02	AQ
ProMIS Neurosciences Achieves Milestone in Development of Therapeutic Alpha-Synuclein Vaccine	22/01	AQ
ProMIS Neurosciences Issues Letter to Shareholders	08/01	AQ
ProMIS Neurosciences, Inc. Announces Leadership Transition	03/01	AQ
ProMIS Neurosciences Announces Publication on Novel Target for ALS	20/12	AQ
ProMIS Neurosciences Doses First Subjects in Phase 1a Clinical Trial of PMN310 to Treat Alzheimer’s Disease	20/11	AQ
ProMIS Neurosciences Announces Third Quarter 2023 Financial Results and Recent Highlights	14/11	AQ
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing	11/09/23	AQ
ProMIS Neurosciences Closes $20.4 Million Private Placement Financing	08/09/23	AQ
PRESSWIRE 2022/2023: PROMIS NEUROSCIENCES TO PRESENT AT THE H.C. WAINWRIGHT 25TH ANNUAL GLOBAL INVESTMENT CONFERENCE	06/09/23	AQ
ProMIS Neurosciences to Present at the H.C. Wainwright 25th Annual Global Investment Conference	06/09/23	AQ
PRESSWIRE 2022/2023: PROMIS NEUROSCIENCES ANNOUNCES $20.4 MILLION PRIVATE PLACEMENT FINANCING	22/08/23	AQ

Aucun résultat pour cette recherche

Toute l'actualité Reco analystes Faits marquants Insiders Transcripts Communiqués Publications officielles Autres langues Idées de trading Articles Zonebourse Analyses Zonebourse

Communiqués ProMIS Neurosciences, Inc.

Actions

PMN

CA74346M4065

Communiqués

Filtres